A variety of chemotherapeutic drugs, falling into three broad categories, have been found to be linked to CRCT: anthracyclines, particularly DOX, HER2 inhibitors trastuzumab, pertuzumab, and T-DM1, as well as other medications, such as the alkylating agent cyclophosphamide, cyclin-dependent kinase inhibitors, immune checkpoint, 5-FU, etc. These medications mainly operate by increasing pro-inflammatory cytokine and reactive oxygen species production, leading to cardiomyocyte damage, and subsequently increasing HF risk. This evidence concerns the gene ERBB2 and hydrops fetalis.